IL155066A - History 2 - Amino - 2 - (2 - Ethyl (converted)) Propane - 1, 3 - Diol Efficacy in the preparation of 2 - Aminopropene - 1, 3 - Diol - Google Patents

History 2 - Amino - 2 - (2 - Ethyl (converted)) Propane - 1, 3 - Diol Efficacy in the preparation of 2 - Aminopropene - 1, 3 - Diol

Info

Publication number
IL155066A
IL155066A IL15506698A IL15506698A IL155066A IL 155066 A IL155066 A IL 155066A IL 15506698 A IL15506698 A IL 15506698A IL 15506698 A IL15506698 A IL 15506698A IL 155066 A IL155066 A IL 155066A
Authority
IL
Israel
Prior art keywords
compound
acid
reaction
present
ethyl
Prior art date
Application number
IL15506698A
Other languages
English (en)
Hebrew (he)
Other versions
IL155066A0 (en
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of IL155066A0 publication Critical patent/IL155066A0/xx
Publication of IL155066A publication Critical patent/IL155066A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/16Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same carbon atom of an acyclic carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/34Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton and at least one hydroxy group bound to another carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C223/00Compounds containing amino and —CHO groups bound to the same carbon skeleton
    • C07C223/02Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
IL15506698A 1997-04-04 1998-04-03 History 2 - Amino - 2 - (2 - Ethyl (converted)) Propane - 1, 3 - Diol Efficacy in the preparation of 2 - Aminopropene - 1, 3 - Diol IL155066A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8625597 1997-04-04
PCT/JP1998/001571 WO1998045249A1 (fr) 1997-04-04 1998-04-03 Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
IL13220898A IL132208A (en) 1997-04-04 1998-04-03 2-aminopropane-1,3-diol derivatives and pharmaceutical compositions containing the same

Publications (2)

Publication Number Publication Date
IL155066A0 IL155066A0 (en) 2003-10-31
IL155066A true IL155066A (en) 2004-06-20

Family

ID=13881722

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13220898A IL132208A (en) 1997-04-04 1998-04-03 2-aminopropane-1,3-diol derivatives and pharmaceutical compositions containing the same
IL15506598A IL155065A (en) 1997-04-04 1998-04-03 History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them
IL15506698A IL155066A (en) 1997-04-04 1998-04-03 History 2 - Amino - 2 - (2 - Ethyl (converted)) Propane - 1, 3 - Diol Efficacy in the preparation of 2 - Aminopropene - 1, 3 - Diol

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL13220898A IL132208A (en) 1997-04-04 1998-04-03 2-aminopropane-1,3-diol derivatives and pharmaceutical compositions containing the same
IL15506598A IL155065A (en) 1997-04-04 1998-04-03 History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them

Country Status (18)

Country Link
US (2) USRE39072E1 (zh)
EP (2) EP1319651B1 (zh)
JP (1) JP4045364B2 (zh)
KR (1) KR100551931B1 (zh)
CN (2) CN1290819C (zh)
AT (2) ATE271028T1 (zh)
AU (1) AU735853B2 (zh)
BR (1) BR9808481A (zh)
CA (1) CA2286315C (zh)
DE (2) DE69830756T2 (zh)
DK (2) DK1319651T3 (zh)
ES (2) ES2226110T3 (zh)
IL (3) IL132208A (zh)
NZ (1) NZ500713A (zh)
PT (2) PT1002792E (zh)
RU (1) RU2198162C2 (zh)
SI (2) SI1319651T1 (zh)
WO (1) WO1998045249A1 (zh)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CZ200350A3 (cs) 2000-07-13 2003-05-14 Sankyo Company Limited Aminoalkoholové deriváty
WO2002029001A2 (en) 2000-10-03 2002-04-11 University Of Virginian Patent Foundation Novel lysophosphatidic acid receptor agonists and antagonists
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
JP2004529100A (ja) 2001-01-30 2004-09-24 ユニバーシティ オブ バージニア パテント ファウンデーション スフィンゴシン−1−ホスフェートレセプターのアゴニストおよびアンタゴニスト
ATE335475T1 (de) * 2001-02-22 2006-09-15 Novartis Pharma Gmbh Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
CZ20032560A3 (cs) 2001-03-26 2003-12-17 Novartis Ag Deriváty 2-aminopropanolu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
DK1389137T3 (da) * 2001-05-21 2006-10-30 Injet Digital Aerosols Ltd Sammensætninger til lungelægemiddellevering af protein
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
WO2003029184A1 (fr) * 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
EP1471054B1 (en) * 2002-01-11 2009-07-01 Daiichi Sankyo Company, Limited Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
NZ536513A (en) 2002-05-16 2007-10-26 Novartis Ag Use of EDG receptor binding agents in cancer
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
AU2003273865A1 (en) 2002-09-13 2004-04-30 Novartis Ag Amino-propanol derivatives
BR0314760A (pt) * 2002-09-24 2005-07-26 Novartis Ag Compostos orgânicos
AU2011205050B2 (en) * 2003-04-08 2014-01-30 Mitsubishi Tanabe Pharma Corporation Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
AU2008200368B2 (en) * 2003-04-08 2011-04-28 Mitsubishi Tanabe Pharma Corporation Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
NZ586280A (en) * 2003-04-08 2011-12-22 Novartis Ag Oral pharmaceutical composition comprising FTY720 and mannitol
CN1777575B (zh) * 2003-04-30 2010-05-12 诺瓦提斯公司 作为1-磷酸-鞘氨醇受体调节剂的氨基-丙醇衍生物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0324210D0 (en) * 2003-10-15 2003-11-19 Novartis Ag Organic compounds
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
EP1733724A4 (en) 2004-02-24 2010-07-07 Sankyo Co Aminoalcohol compound
CA2563569A1 (en) * 2004-05-03 2005-11-10 Novartis Ag Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
WO2005115150A2 (en) 2004-05-06 2005-12-08 University Of Virginia Patent Foundation Novel lysophosphatidic acid receptor selective antagonists
GB0411929D0 (en) * 2004-05-27 2004-06-30 Novartis Ag Organic compounds
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
DK1772145T3 (da) 2004-07-16 2011-05-30 Kyorin Seiyaku Kk Fremgangsmåde til effektiv anvendelse af medicin og fremgangsmåde til forebyggelse af bivirkninger
JP4919374B2 (ja) * 2004-07-29 2012-04-18 第一三共株式会社 免疫抑制剤としての医薬組成物
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
CA2574664C (en) 2004-07-30 2013-01-15 Novartis Ag Compound formulations of 2-amino-1,3-propanediol compounds
RU2007109207A (ru) * 2004-08-13 2008-09-20 Прикис Фамэсьютикэлс, Инк. (US) Соединения-модуляторы активности рецептора сфингозин-1-фосфата (варианты), фармацевтическая композиция, содержащая указанные соединения, и способ лечения нарушения, ассоциированного со сфингозин-1-фосфатом
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
US7795472B2 (en) * 2004-10-12 2010-09-14 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride and hydrates thereof, and intermediates in the production thereof
MX2007006373A (es) 2004-11-29 2007-06-20 Novartis Ag Regimen de dosificacion de un agonista del receptor s1p.
EP1850865A2 (en) * 2005-02-08 2007-11-07 Novartis AG Antilymphocyte antibody induction by combination of an s1p receptor agonist/modulator and of immunosuppressive drugs
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
TW200702326A (en) * 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ppar調節劑之醫藥組成物的用途
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
SI1932522T1 (sl) * 2005-10-07 2012-08-31 Kyorin Seiyaku Kk Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
UA100666C2 (uk) 2006-04-11 2013-01-25 Новартіс Аг Інгібітори нсv/віл та їх застосування
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
TW200815600A (en) 2006-08-04 2008-04-01 Daiichi Sankyo Co Ltd An enzyme for phosphorizing a medicine
CA2659599C (en) * 2006-08-08 2014-06-17 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
CN101501049B (zh) * 2006-08-08 2013-04-24 杏林制药株式会社 氨基磷酸酯衍生物以及将它们作为有效成分的s1p受体调节剂
KR20090057399A (ko) 2006-09-26 2009-06-05 노파르티스 아게 S1p 조정제를 포함하는 제약 조성물
WO2008121709A1 (en) * 2007-03-30 2008-10-09 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
ES2581879T3 (es) 2007-06-14 2016-09-08 Mitsubishi Tanabe Pharma Corporation Compuesto de amina y su uso farmacéutico
DE102007039954A1 (de) * 2007-08-23 2009-02-26 Henkel Ag & Co. Kgaa Reduktive Entfärbung keratinhaltiger Fasern
CA2925175A1 (en) 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US9657043B2 (en) 2012-04-23 2017-05-23 Mitsubishi Tanabe Pharma Corporation Amine compound and use thereof for medical purposes
CN110862409B (zh) * 2019-12-04 2021-08-20 江南大学 一种制备含二元醇结构的硅烷类化合物及其改性水性聚氨酯的方法
US20220153684A1 (en) * 2020-11-13 2022-05-19 Shivalik Rasayan Limited Process for preparation of fingolimod hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660488A (en) * 1965-07-16 1972-05-02 Phillips Petroleum Co 2-halo-alkylene- and -cyclopentylene-2-amino-propane 1 3-diols
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
ATE211726T1 (de) * 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung

Also Published As

Publication number Publication date
AU735853B2 (en) 2001-07-19
EP1319651A2 (en) 2003-06-18
CN1137086C (zh) 2004-02-04
SI1002792T1 (en) 2004-12-31
DE69825056T2 (de) 2005-08-25
KR100551931B1 (ko) 2006-02-16
US6214873B1 (en) 2001-04-10
BR9808481A (pt) 2000-05-23
AU6523098A (en) 1998-10-30
CN1480450A (zh) 2004-03-10
CA2286315C (en) 2007-03-06
ES2226110T3 (es) 2005-03-16
EP1002792A1 (en) 2000-05-24
CN1290819C (zh) 2006-12-20
NZ500713A (en) 2000-07-28
ATE271028T1 (de) 2004-07-15
WO1998045249A1 (fr) 1998-10-15
USRE39072E1 (en) 2006-04-18
SI1319651T1 (en) 2005-10-31
RU2198162C2 (ru) 2003-02-10
DK1002792T3 (da) 2004-11-22
EP1002792B1 (en) 2004-07-14
DE69830756D1 (de) 2005-08-04
DE69830756T2 (de) 2006-05-04
EP1319651A3 (en) 2004-01-02
EP1002792A4 (en) 2002-03-20
IL155065A (en) 2004-01-04
DE69825056D1 (de) 2004-08-19
KR20010006004A (ko) 2001-01-15
CA2286315A1 (en) 1998-10-15
IL155066A0 (en) 2003-10-31
IL155065A0 (en) 2003-10-31
EP1319651B1 (en) 2005-06-29
CN1259117A (zh) 2000-07-05
PT1319651E (pt) 2005-09-30
ES2240868T3 (es) 2005-10-16
JP4045364B2 (ja) 2008-02-13
PT1002792E (pt) 2004-12-31
IL132208A0 (en) 2001-03-19
IL132208A (en) 2003-07-31
DK1319651T3 (da) 2005-08-01
ATE298740T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
EP1319651B1 (en) 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
AU705320B2 (en) 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof for use in the preparation of a non-oral medicament, and for treatment of diseases and disorders
WO2005014525A2 (en) Bi-aryl compound having immunosuppressive activity
US20090176744A1 (en) Deuterated fingolimod
JPH10182583A (ja) 新規ヒドロキサム酸誘導体
US20050020541A1 (en) Silicon compounds
US20100184862A1 (en) Prostacyclin derivatives
AU2002339071A1 (en) Silicon compounds
WO2005014603A1 (en) Phosphinane compounds with immunomodulating activity
FR2656221A1 (fr) Compositions therapeutiques a base de derives du glycerol.
EP1562611B1 (en) Heterocyclic silicon compounds and their use in the treatment of diseases or conditions associated with gnrh (gonadotropin-releasing hormone)
MXPA99009124A (en) 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH0322394B2 (zh)
JPH10147587A (ja) 2−アミノ−1,3−プロパンジオール誘導体およびその医薬用途
JP2006213599A (ja) 2−アミノプロパン−1,3−ジオール化合物およびその医薬用途
RU2015964C1 (ru) Способ получения замещенных производных амина
TW202339766A (zh) 非環狀硫醇前藥
JP2009522380A (ja) 抗腫瘍活性を有するタキソール誘導体
JPH0322395B2 (zh)
WO2004094436A1 (en) 1-(2-amino-1-phenyl-ethyl) 1- silacyclohexan-1- ol derivatives and use thereof in the preparation of a medicament

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees